Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$99.26

-0.63 (-0.63%)

14:39
10/09/16
10/09
14:39
10/09/16
14:39

TESARO reports Phase 3 data on niraparib in ovarian cancer, says met endpoint

TESARO announced the presentation of the niraparib Phase 3 ENGOT-OV16/NOVA clinical trial results at the ESMO 2016 Congress. ENGOT-OV16/NOVA is a Phase 3 trial of niraparib that enrolled 553 patients with recurrent ovarian cancer who were in response to their most recent platinum-based chemotherapy. The trial successfully achieved its primary endpoint in both cohorts, demonstrating that niraparib treatment significantly prolonged PFS compared to control in patients who were germline BRCA mutation carriers and in patients who were not germline BRCA mutation carriers. In addition, within the non-gBRCA cohort, niraparib treatment significantly prolonged PFS compared to control for the prospectively defined patient population with tumors deficient in homologous recombination. Specifically, among patients who were germline BRCA mutation carriers, the niraparib arm successfully achieved statistical significance over the control arm for the primary endpoint of PFS, with a hazard ratio of 0.27. The median PFS for patients treated with niraparib was 21.0 months, compared to 5.5 months for control. Niraparib also showed statistical significance for patients in the non-germline BRCA mutant cohort. The niraparib arm successfully achieved statistical significance over the control arm for the primary endpoint of PFS, with a hazard ratio of 0.45. The median PFS for patients treated with niraparib was 9.3 months, compared to 3.9 months for control. For patients who were not germline BRCA mutation carriers but whose tumors were determined to be HRD positive, the niraparib arm successfully achieved statistical significance over the control arm for the primary endpoint of PFS, with a hazard ratio of 0.38. The median PFS for patients with HRD-positive tumors who were treated with niraparib was 12.9 months, compared to 3.8 months for control. Secondary endpoint analyses, including chemotherapy-free interval, time to first subsequent treatment, and PFS 2 were all statistically significant and favored niraparib over control for patients in both the gBRCAmut and non-gBRCAmut cohorts. Patient-reported outcome results from validated survey tools indicated that niraparib-treated patients reported no difference from control in measures associated with quality of life. Data for overall survival are immature, as fewer than 20% of events had occurred at the time of analysis. The most common treatment-emergent grade 3/4 adverse events in the niraparib arm were thrombocytopenia in 33.8%, anemia in 25.3%, and neutropenia in 19.6%. The majority of these hematological laboratory abnormalities occurred within the first three cycles; following dose modifications the incidence of these lab abnormalities decreased and thrombocytopenia and neutropenia were infrequent beyond cycle 3. There were no deaths among patients during study treatment. A high proportion of patients in both treatment groups in both cohorts had received three or more prior lines of chemotherapy.

  • 06

    Nov

  • 11

    Jan

TSRO Tesaro
$99.26

-0.63 (-0.63%)

09/21/16
09/21/16
NO CHANGE

RBC identifies top biotech takeover candidates
RBC Capital identified the following names as its top potential takeover candidates in the biotech space: ARIAD (ARIA), Spark Therapeutics (ONCE), BioMarin (BMRN), Aerie Pharmaceuticals (AERI), Intra-Cellular (ITCI), TESARO (TSRO), Incyte (INCY), Sarepta (SRPT), and Puma Biotechnology (PBYI). The firm thinks that investors are underestimating the positive impact that M&A will have on biotech stock prices.
09/21/16
LEER
09/21/16
NO CHANGE
LEER
Outperform
PARP addition makes sense for Eli Lilly oncology, says Leerink
In the wake of recent speculation that Eli Lilly (LLY) has expressed interest in acquiring Clovis (CLVS), Leerink analyst Seamus Fernandez says the addition of a PARP inhibitor makes strategic sense, fitting in "extremely well" with the former's oncology portfolio. Further, the analyst believes that the "impressive" emerging data from the PARP inhibitor class is likely to place both TESARO (TSRO) and Clovis high on the list of potential M&A targets. Fernandez reiterates an Outperform rating on Eli Lilly's shares.
09/26/16
BOFA
09/26/16
NO CHANGE
Target $109
BOFA
Buy
TESARO price target raised to $109 from $95 at BofA/Merrill
BofA/Merrill analyst Doug Leggate raised Teseor's price target to $109 from $95 following management meetings that suggest current EBITDA is about $800M, ahead of management targets. Shares are Buy rated.
10/07/16
PIPR
10/07/16
NO CHANGE
PIPR
Neutral
Piper still sees Clovis' rucaparib getting broader indication than Lynparza
Piper Jaffray analyst Steven Breazzano said the rucaparib response rates in platinum resistant and platinum refractory patients of 25% and 0%, respectively, reported by Clovis Oncology (CLVS) are lower than some may have been expecting and "seemingly negative on the surface." However, he continues to believe rucaparib will be approved in BRCA patients who have received 2+ lines of therapy, which is an earlier and broader patient population than assigned to competitor AstraZeneca's (AZN) Lynparza, he tells investors. The ultimate market potential and key to success is the maintenance setting, for which TESARO's (TSRO) niraparib is still best-positioned, adds Breazzano, who keeps a Neutral rating on Clovis shares.

TODAY'S FREE FLY STORIES

UBNT

Ubiquiti

$50.62

-4.335 (-7.89%)

09:26
09/19/17
09/19
09:26
09/19/17
09:26
Hot Stocks
Ubiquiti Board approves additional $100M stock repurchase program »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

UBNT

Ubiquiti

$50.62

-4.335 (-7.89%)

09:23
09/19/17
09/19
09:23
09/19/17
09:23
Earnings
Ubiquiti narrows Q1 revenue view to $240M-$250M, consensus $234.5M »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

LNDC

Landec

$12.80

-0.2 (-1.54%)

09:22
09/19/17
09/19
09:22
09/19/17
09:22
Hot Stocks
Landec provides update on impact from extreme weather events »

Landec provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

BOBE

Bob Evans

$72.93

1.02 (1.42%)

, POST

Post Holdings

09:19
09/19/17
09/19
09:19
09/19/17
09:19
Hot Stocks
On The Fly: Pre-market Movers »

HIGHER: Bob Evans (BOBE),…

BOBE

Bob Evans

$72.93

1.02 (1.42%)

POST

Post Holdings

AZO

AutoZone

TLGT

Teligent

$6.90

-0.29 (-4.03%)

WBA

Walgreens Boots Alliance

$82.60

0.1 (0.12%)

RAD

Rite Aid

APOG

Apogee Enterprises

$44.98

0.18 (0.40%)

EFX

Equifax

ALDX

Aldeyra

$9.10

0.2 (2.25%)

SNCR

Synchronoss

$16.75

0.64 (3.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 21

    Sep

  • 22

    Sep

  • 27

    Sep

  • 27

    Sep

  • 28

    Sep

  • 30

    Oct

  • 19

    Sep

PG

Procter & Gamble

09:19
09/19/17
09/19
09:19
09/19/17
09:19
Hot Stocks
Peltz says not asking for P&G CEO David Taylor to step down »

Nelson Peltz of Trian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOX

Amdocs

$64.13

1.64 (2.62%)

09:19
09/19/17
09/19
09:19
09/19/17
09:19
Conference/Events
Amdocs participates in a conference call with Oppenheimer »

Conference call for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYL

Tyler Technologies

09:18
09/19/17
09/19
09:18
09/19/17
09:18
Hot Stocks
Tyler Technologies selected by Odessa, Texas for ERP solution »

Tyler Technologies signed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

09:18
09/19/17
09/19
09:18
09/19/17
09:18
Options
Overnight activity included 97 trades in SPX and 67 trades in VIX »

97 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APD

Air Products

09:16
09/19/17
09/19
09:16
09/19/17
09:16
Hot Stocks
Air Products awarded oxygen supply contract by South Korean chemical company »

Air Products has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPIC

TPI Composites

$20.98

-0.05 (-0.24%)

, XYL

Xylem

09:15
09/19/17
09/19
09:15
09/19/17
09:15
Conference/Events
Cowen to hold a summit »

Industrial Innovation…

TPIC

TPI Composites

$20.98

-0.05 (-0.24%)

XYL

Xylem

WLDN

Willdan Group

$29.79

0.71 (2.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 28

    Sep

MDLZ

Mondelez

$40.71

-0.15 (-0.37%)

, PG

Procter & Gamble

09:15
09/19/17
09/19
09:15
09/19/17
09:15
Hot Stocks
Peltz says Mondelez price raises were due to higher cocoa prices »

Nelson Peltz of Trian is…

MDLZ

Mondelez

$40.71

-0.15 (-0.37%)

PG

Procter & Gamble

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

AVAV

AeroVironment

$49.13

0.64 (1.32%)

, BMWYY

BMW

$33.78

-0.03 (-0.09%)

09:14
09/19/17
09/19
09:14
09/19/17
09:14
Hot Stocks
AeroVironment's TUrboCord selected as official EV charging accessory by BMW »

AeroVironment (AVAV)…

AVAV

AeroVironment

$49.13

0.64 (1.32%)

BMWYY

BMW

$33.78

-0.03 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

SCI

Service Corp.

09:14
09/19/17
09/19
09:14
09/19/17
09:14
Conference/Events
Service Corp. management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

CARB

Carbonite

$21.70

1.2 (5.85%)

09:13
09/19/17
09/19
09:13
09/19/17
09:13
Earnings
Carbonite backs Q3 EPS view of 19c-21c, consensus 21c »

Backs Q3 revenue guidance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

PG

Procter & Gamble

09:11
09/19/17
09/19
09:11
09/19/17
09:11
Hot Stocks
Peltz says Procter & Gamble losing market share year after year »

Nelson Peltz of Trian is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UFCS

United Fire Group

$41.51

-0.41 (-0.98%)

09:10
09/19/17
09/19
09:10
09/19/17
09:10
Hot Stocks
Breaking Hot Stocks news story on United Fire Group »

United Fire Group trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:10
09/19/17
09/19
09:10
09/19/17
09:10
General news
Treasury Action: yields rebounded from lows »

Treasury Action: yields…

JPM

JPMorgan

$92.92

1.3 (1.42%)

09:09
09/19/17
09/19
09:09
09/19/17
09:09
Conference/Events
The Business Roundtable releases 3Q17 CEO Economic Outlook Survey »

The Business Roundtable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

P

Pandora

$8.19

0.07 (0.86%)

09:07
09/19/17
09/19
09:07
09/19/17
09:07
Hot Stocks
Pandora launches Video Plus for all advertisers »

Pandora announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADXS

Advaxis

$4.95

0.14 (2.91%)

09:06
09/19/17
09/19
09:06
09/19/17
09:06
Hot Stocks
Advaxis to present two abstracts on Lm-based candidates at STIC meeting »

Advaxis announced two…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

CVM

CEL-SCI

$1.62

0.03 (1.89%)

09:06
09/19/17
09/19
09:06
09/19/17
09:06
Hot Stocks
CEL-SCI announces $1.5M NIH SBIR grant for RA vaccine development »

CEL-SCI Corporation has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JMBA

Jamba

$9.10

0.07 (0.78%)

09:05
09/19/17
09/19
09:05
09/19/17
09:05
Hot Stocks
Jamba receives Nasdaq staff determination letter, intent to request hearing »

Jamba, Inc. received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHFC

Chemical Financial

$49.32

0.71 (1.46%)

09:05
09/19/17
09/19
09:05
09/19/17
09:05
Downgrade
Chemical Financial rating change  »

Chemical Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:05
09/19/17
09/19
09:05
09/19/17
09:05
General news
U.S. equities turned mixed »

U.S. equities turned…

RLJ

RLJ Lodging Trust

$21.82

0.22 (1.02%)

, FCH

Felcor Lodging

09:04
09/19/17
09/19
09:04
09/19/17
09:04
Hot Stocks
RLJ Lodging announces change of control offer for FelCore's senior secured notes »

RLJ Lodging Trust (RLJ)…

RLJ

RLJ Lodging Trust

$21.82

0.22 (1.02%)

FCH

Felcor Lodging

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.